1556 results about "Helicobacter pylori gastritis" patented technology

An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.

The invention provides a health-care flour composition and food and a preparing method thereof. According to the preparing method, hericium erinaceus and flour are used as main raw materials, swelling agents, sweetening agents, oil, salt and the like are added and mixed with water, and then rolling, forming, baking, oil injection and cooling are carried out to obtain various foods made of flour or pastries such as cookies, cakes and noodles. The health-care flour composition and food are even in texture, capable of being stored for a long time easily, good in mouthfeel and rich in nutrient, and market vacancy is filled. The health-care flour composition and food have definite effects in repairing gastric mucosal damage caused by chronic gastritis, or gastric ulcers or duodenal ulcers, relieving abdominal pains caused by chronic gastritis, or gastric ulcers or duodenal ulcers, inhibiting helicobacter pylori, and assisting the treatment of chronic gastritis, gastric ulcers and duodenal ulcers.

A breath test for diagnosing the presence of Helicobacter pylori in a subject is described. The method of diagnosing Helicobacter pylori is performed as follows. First, a safe and effective amount of urea, preferably appropriately labelled, is administered to the subject. Second, a plurality of the exhaled breaths of the subject is analyzed to detect the concentration of a cleavage product or products, produced when urease cleaves the substrate. The measured concentrations are then fitted to a curve, and the derivative is then calculated, to indicate the presence or absence of Helicobacter pylori infection in the subject.

The present invention relates to methods of preventing or inhibiting the growth of Helicobacter through the use of a composition that comprises a glucosinolate, an isothiocyanate or a derivative or metabolite thereof. The present invention also relates to methods of preventing or treating persistent chronic gastritis, ulcers and / or stomach cancer in subjects at risk for, or in need of treatment thereof.

The present invention relates to a devices and methods for killing and / or debilitating pathogenic microorganisms in or on a patient's body, such as light-sensitive bacteria including helicobacter pylori and / or propionibacterium acnes. A chemiluminescent light source provides electromagnetic radiation having predetermined wavelengths in the visible spectrum. The light wavelengths are selected for absorption by naturally-occurring photosensitive chemicals produced by the patient's body.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

The invention relates to an automated decision support system, method, and apparatus for analysis and detection of bacteria in histological sections from tissue biopsies in general, and more specifically, of Helicobacter pylori (HP) in histological sections from gastric biopsies. The method includes image acquisition apparatus, data processing and support system conclusions, methods of transferring and storing the slide data, and pathologist diagnosis by reviewing and approving the images classified as containing bacteria, and more specifically HP findings.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

PCT No. PCT / SE95 / 01212 Sec. 371 Date May 29, 1997 Sec. 102(e) Date May 29, 1997 PCT Filed Oct. 17, 1995 PCT Pub. No. WO96 / 14091 PCT Pub. Date May 17, 1996A preparation for administering isotope-labelled urea together with acid in a solid form that is influenced by activity of Helicobacter pylori in the stomach only, avoiding any non-Helicobacter (unspecific) urease activity in the oral cavity and the pharynx. The preparation dissolves very quickly in the stomach. The preparation is used to show increased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.

Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and / or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. In some embodiments, the Helicobacter provides exposure of a desired molecule of interest though the surface of the Helicobacter, providing exposure of the antigen to the host at the gastric mucosa. Live Helicobacter pylori vaccines are also provided. Vectors and shuttle vector constructs of the Helicobacter are also disclosed.

The invention relates to lactobacillus CN2018, CGMCC No. 4286 and application thereof. The lactobacillus CN2018 has acid resistance, has an effect of suppressing growth of helicobacter pylori (H. pylori SS1 for instance) and urease activity, has a stronger effect of suppressing the adherence of helicobacter pylori to human gastric epithelial cells SGC7901, and has an effect of preventing or relieving infection degree of mice infection of the helicobacter pylori.

The invention discloses a method for building a helicobacter pylori nucleic acid fingerprint spectrum, which comprises PCR (polymerase chain reaction) amplification, SAP (severe acute pancreatitis) enzymatic digestion, transcription and nuclease digestion, purification, mass spectrometer detection and the like. A helicobacter pylori nucleic acid fingerprint spectrum database is set up on the basis of the method. According to the generated mass peak spectrum of the experiment, the helicobacter pylori of a sample to be detected can be quickly identified, so the method can be widely applied in the fields of helicobacter pylori types and classification, environmental sanitation, public safety qunarantine and the like.

The present invention is an orally-administrable composition for preventing and treating Helicobacter pylori-associated stomach gastritis and ulcers, and for preventing Helicobacter pylori-associated stomach cancer. The invention is a herb or herb extract containing an anti-H. pylori activity. The invention further includes methods for making and methods for using the invention.

Live strains of Lactococcus sp. HY 49, Lactobacillus casei HY 2782, and Bifidobacterium longum HY 8001 maintained in nutritious foods, such as yogurt, imbue them with prophylactic and / or therapeutic properties. Such foods are beneficial in the prevention and / or treatment of gastritis, duodenal and gastric ulcers caused by infection from Helicobacter pylori (also referred to as H. pylori). The properties of these bacteria are boosted by the addition of egg yolk containing antibodies specific to H. pylori antigen derived from "fractionated H. pylori".

The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for Helicobacter Pylori infection. This composition inhibits growth of Helicobacter pylori, and can increase the antioxidant activity of gastric mucosal cells through reducing the production of O2.−, H2O2 and NO, and decreasing the expression of inducible nitric oxide synthase (iNOS) in cells. The apoptotic damage of stomach caused by Helicobacter pylori was decreased through up-regulation of autophagy to enhance the defensive ability of gastric epithelial cells toward Helicobacter pylori. Therefore the composition can be used in the treatment or prevention on damages caused by Helicobacter pylori infection.

An anti-Helicobacter pylori agent comprising a compound represented by the formula:wherein A represents an aromatic ring group which may be substituted; R1 and R2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substituted; R3 and R4, whether identical or not, each represent a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group, a carbamoyl group which may be substituted, or a carboxyl group which may be esterified; or a salt thereof.

A process for producing an antibody enzyme which involves an antibody structure analysis step of confirming the presence of a catalyst triplet residue structure wherein a serine residue, an aspartate residue and a histidine residue or a glutamate residue are located stereostructurally close to each other in the stereostructure of an antibldy anticipated based on its amino acid sequence. Since the above-described catalyst triplet residue structure is a structure specific to an antibody enzyme, an antibody enzyme can be efficiently screened by using the same. Examples of the antibody enzyme as described above include an antibody enzyme against Helicobacter pylori urease and an antibody enzyme against chemokine receptor CCR-5.

The invention discloses a compound bismuth composition which contains antibiotics, a coated tablet of antibacterial agent and bismuth particle or powder, wherein the coated tablet is coated with Opadry II and the coating amount is 3 percent by weight; and the weight ratio of bismuth to the antibiotics to the antibacterial agent is 4-35:5-50:5-50. The invention also discloses a preparation method of the compound bismuth composition. The compound bismuth composition achieves good balance between the mutual action among active ingredients and the action of the active ingredients performed in stomach, and therefore is used for better eliminating the helicobacter pylori of stomach.

The present invention provides one kind of genetic engineering multivalent subunit vaccine for preventing and treating human helicobacter pylori infection and its preparation process. The vaccine consists of active helicobacter pylori UreB fragment UreB414 as the central antigen component, other combined protective antigens, and intramolecular or extramolecular adjuvant. Compared with univalent vaccine, the multivalent combined vaccine can stimulate the body to generate more powerful and more comprehensive helicobacter pylori resisting specific immune reaction.

Novel methods, membrane supports and immunodiagnostic test kits for diagnosing Helicobacter pylori infection, are disclosed. The methods can also be used to monitor the progress of treatment of an infection. The methods, supports and kits employ both type-common and type-specific H. pylori antigens and can conveniently be performed in a single-step assay format. The methods provide for highly accurate results and discriminate between H. pylori Type I and H. pylori Type II infection so that an accurate diagnosis can be accomplished.

PCT No. PCT / SE97 / 00098 Sec. 371 Date Jul. 22, 1998 Sec. 102(e) Date Jul. 22, 1998 PCT Filed Jan. 22, 1997 PCT Pub. No. WO97 / 26908 PCT Pub. Date Jul. 31, 1997Use of an antibacterial system comprising lactoperoxidase and a peroxide donor for preparing a preparation for prophylactic or therapeutic treatment "in vivo" of an infection caused by the bacteria Helicobacter pylori existing in the stomach, which preparation is completed by the presence of thiocyanate in an antibacterial level, and eventually in the presence of lactoferrin. A daily dose for human treatment is 1.2-1.6 grams of the system taken 3 times a day.

Disclosed are a composition for detecting Helicobacter pylori including urea 0.5 to 4 percent by volume, potassium phosphate 0.05 to 0.2 percent by volume, phenate reagent solution 0.8 to 1.7 percent by volume, an indicator having a pKa of 6.5 to 8.5, 0.002 to 0.005 percent by volume, and a balance of water, a kit for detecting Helicobacter pylori using the composition and detecting method using the composition can determine quickly and accurately whether or not an infection by Helicobacter pylori exists, can obtain the same determination results after an elapse of time and can be used easily in an endoscope chamber.

The invention relates to compound probiotics and a preparation method thereof. The compound probiotics comprise ten or more probiotics and two or more prebiotics. The invention also provides the preparation method of the compound probiotics. The preparation method comprises the following steps: firstly, mixing the compound probiotics according to the proportion, passing through a sieve with 80 to 120 meshes, then taking siftage and weighing; secondly, mixing the weighed materials; thirdly, tabletting mixed materials. According to the compound probiotics and the preparation method thereof disclosed by the invention, by scientifically mixing the probiotics with the prebiotics, the efficacy of the compound probiotics is effectively improved, living cell concentration is high, and the efficacy realizing time of the probiotics is shortened; compared with other products in the market, the compound probiotics have the advantages that acid and bile salt resisting capabilities are good; if the compound probiotics are administrated for one month, the improvement rate of constipation reaches 100 percent, the improvement rate of chronic colitis reaches 100 percent, the positive-to-negative rate of helicobacter pylori reaches 82 percent, the rehabilitation rate of chemical liver injury reaches 88 percent, the rehabilitation rate of anaphylactic rhinitis is 91 percent, the rehabilitation rate of female vaginitis reaches 93 percent, the improvement rate of phlegm-dampness constitution reaches 100 percent, the improvement rate of damp-heat constitution reaches 100 percent, and the improvement rate of acnes reaches 98 percent.

The invention relates to the field of the emulsion method immune chromatography, and particularly relates to a detection kit of a helicobacter pylori emulsion method. The detection kit of the helicobacter pylori emulsion method comprises a reagent strip, wherein the reagent strip comprises a substrate, filter sample paper, a sensitized emulsion polyester film, an immune cellulose nitrate film and absorbent paper, wherein the filter sample paper, the sensitized emulsion polyester film, the immune cellulose nitrate film, and the absorbent paper are orderly connected end to end, and are fixed on the substrate, the immune cellulose nitrate film is covered with helicobacter pylori resisting urea enzyme antibodies I marked by colorful emulsion particles, and the immune cellulose nitrate film is provided with a detection line coated with helicobacter pylori resisting urea enzyme antibodies II and a quality control line coated by goat anti-rabbit serum IgG. The detection kit of the helicobacter pylori emulsion method, which is provided by the invention, has the advantages of convenience in detection, stability in detection results and cost conservation.

The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

The invention discloses a method and a device for detecting and separating HP ELISA. According to the method, a prepared magnetic bead provided with HP, an enzyme-labeled antibody, an enzyme reaction substrate, a gastric juice sample and a cleaning fluid are placed in different liquid storage tanks on a micro-fluidic chip by the aid of an electric fluid force, and flow of liquids in the different liquid storage tanks is electrically controlled , so that ELISA is fully and automatically detected; and a detected fluorescence signal is taken as a trigger signal, so that an HP sample is fully and automatically separated. The device comprises a platform structure, the micro-fluidic chip and an electric cabinet, wherein the micro-fluidic chip comprises a glass sheet, a PDMS (polydimethylsiloxane) square plate and a driving electrode, a micro channel, a mixed channel and a detection area are formed in the surface of the PDMS square plate in a photoetching manner by the aid of a soft lithography technology, and the liquid storage tanks are arranged on the PDMS square plate. The device for detecting and separating the HP ELISA has the advantages as follows: the device is small in size, light in weight, convenient to carry and operate and low in construction cost and can be handheld for field detection, thereby facilitating popularization and application.

The invention belongs to the technical field of helicobacter pylori (Hp) examination and discloses a kit for fast culture, identification and a drug sensitivity test of Hp and an examination method therefor. The kit comprises a first culture tube, an identification reagent device and a drug sensitivity test unit. Through the first culture tube of Hp, bedside inoculation of a specimen is realized and the traditional sample transport and preservation processes are avoided; ordinary thermostat culture is realized and dependence on a CO2 incubator is eliminated; an Hp growth result is represented by a color change so that a result can be determined accurately by laypeople; through the combination of a growth promoting agent and a growth indicator, culture time is shortened and fast culture of Hp is realized; an Hp identification reagent, fast combination identification of Hp is realized; and through the drug sensitivity test unit of Hp, fast and accurate examination of drug sensitivity of Hp is realized. The kit and the examination method therefor can realize fast and accurate examination of Hp.

The invention belongs to the fields of genetic engineering and medical inspection, and relates to a biochip for detecting drug resistant genes of drug resistant genes and a preparation method and an application thereof. The biochip is prepared by the following steps: carrying out aldehyde processing for a chip base; connecting a 5' end of a probe with a molecule arm of poly (dT)10; then carrying out amino modification for the 5' end of the probe; aiming at the mutants at the following positions of helicobacter pylori 23S rRNA genes by the probe: A2115G, A2142G, A2142C, A2143G, A2143C, T2182C and G2224A; and fixing the probe on the chip base. The biochip has high sensitivity, good specificity and low detection cost, can distinguish the difference of monobasic bases, and is suitable for being popularized and used in establishment units.

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), E. coli O157:H7, fluoroquinolone-resistant Salmonella typhi, and the like. Furthermore, in the present methods, gallium compounds can be co-administered with one or more conventional antimicrobial agents to treat infectious diseases with reduced risks of creating multi-drug resistant pathogens. The methods of the present invention is also applicable to those microorganisms, such as ulcer-causing Helicobacter pylori, complete eradication of which so far has been difficult to achieve.

The invention provides an r-lansoprazole for injection and a preparation method thereof. The medicament comprises active components of r-lansoprazole, or r-lansoprazole salt or r-lansoprazole water crystal as well as an excipient, a pH regulator and an antioxidizer. The preparation method comprises the following steps of: dissolving raw and auxiliary materials in water; adjusting the pH value; adding active carbon to decolor; filtering with a filter membrane; sub-packaging; freezing and drying to obtain the r-lansoprazole. The medicament is clinically used for treating gastric ulcer, duodenal ulcer, erosive gastro-esophageal reflux disease, helicobacter pylori, zollinger-ellison syndrome, and the like, can prevent the orally taken r-lansoprazole from being damaged in gastric acid and reach the aims of fast onset and improving the bioavailability.